Melanoma: adjuvant therapy and other treatment options
Related Experiment Video
Updated: Sep 26, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Alicia Terando1, Michael S Sabel, Vernon K Sondak
1University of Michigan Comprehensive Cancer Center, 3304 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
Abstract:
Melanoma, diagnosed and treated at its earliest stages, can be successfully cured by surgery alone. However, when metastatic beyond the regional nodes, it is almost uniformly deadly. Adjuvant therapy targeted toward the treatment of microscopic residual disease after surgical resection is the subject of intense scientific investigation because this is the stage at which it is possible to have the greatest impact on disease-free and overall survival. However, standard therapies commonly used for other solid tumors have had disappointing results in the treatment of melanoma in the adjuvant setting. These disappointing results have led researchers and clinicians to work to develop innovative treatment strategies for this disease, most of which center on the use of immunotherapy. The realm of cancer immunotherapy is broad and rapidly expanding; it encompasses strategies using immunomodulating agents, such as interferon and interleukin-2, in addition to a wide range of novel vaccination strategies for the induction of active antitumor immune responses. Although clinical trials continue to be conducted to sort out the safety and efficacy of a myriad of new treatment modalities and novel combinations of the old and the new, data indicate that high-dose interferon-alfa-2b should be offered to appropriately selected intermediate- and high-risk patients with melanoma not involved in an experimental protocol.
Insights
Early-stage melanoma is curable with surgery. For advanced melanoma, immunotherapy, particularly high-dose interferon-alfa-2b, shows promise in treating microscopic residual disease to improve survival.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Melanoma is curable when detected early, but metastatic disease is often fatal.
- Adjuvant therapy is crucial for treating microscopic residual disease after surgery to improve survival.
- Standard therapies for other cancers have shown limited success in adjuvant melanoma treatment.
Purpose of the Study:
- To investigate innovative treatment strategies for melanoma, focusing on immunotherapy.
- To evaluate the role of adjuvant therapy in improving disease-free and overall survival for melanoma patients.
- To identify effective treatments for microscopic residual disease in intermediate- and high-risk melanoma patients.
Main Methods:
- Review of current scientific investigations and clinical trials in melanoma adjuvant therapy.
- Analysis of immunotherapeutic strategies, including immunomodulating agents and vaccination.
- Evaluation of data on high-dose interferon-alfa-2b in clinical settings.
Main Results:
- Standard adjuvant therapies have yielded disappointing results in melanoma.
- Immunotherapy, including interferon and novel vaccines, is a rapidly expanding area of research.
- High-dose interferon-alfa-2b is recommended for selected intermediate- and high-risk melanoma patients outside of experimental protocols.
Conclusions:
- Innovative treatment strategies, primarily immunotherapy, are needed for advanced melanoma.
- High-dose interferon-alfa-2b is a viable adjuvant treatment option for specific melanoma patient groups.
- Continued research into novel therapies and combinations is essential for improving melanoma outcomes.
Related Concept Videos
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...